PPT-RESPONSE TO RFP Assays for treatment monitoring in tuberculosis drug studies

Applicant Name Address Contact Information Overview of Assay Summary of technology Key assay features Time to result Existing assay menu Current specimen types accepted Assay readouts incl quantitative results. Why do we test?. 1. We want to prevent an outbreak of Tuberculosis in our campus community. 2. We want to find those that are affected and get them treated so you are able to continue to participate in your schooling. . Head of Statistics for Internal Medicine RU . Early Clinical Devel. opment. Pfizer. Is High Placebo Response Really a Problem in Clinical Trials?. The Placebo Response “Problem”. Typical response to a failed drug trial “The study failed due to an unexpectedly high placebo response……”. Mycobacterial . Disease. . Increasing . Role for Surgery, Relearning Old Lessons. John D. Mitchell, M.D.. Professor and Chief. Section of General Thoracic Surgery. Davis Endowed Chair in Thoracic Surgery. Treatment of Latent . Tuberculosis Infection and Tuberculosis. Disease . Module 4 – Treatment of Latent Tuberculosis Infection and Tuberculosis Disease. 2. Module 4: Objectives. At completion of this module, learners will be able to:. Akujobi. CN, . Okoro. CE, . Anyabolu. AE, . Okonkwo. RC, . Onwunzo. MC and . Chukwuka. CP. Tuberculosis (TB) is the most common opportunistic infection in Human . Immuno. d. eficiency . Virus (HIV. Eric Bihler. Objectives . Brief overview of epidemiology and transmission. Differentiate between latent and active tuberculosis. Treatment of tuberculosis. Common side effects of therapy. I. ntroduction. Mrs.Indumathi. Lecturer . YNC. OBJECTIVE. By the end of the session the student will be able to:. define tuberculosis. explain the epidemiological triad of tuberculosis. identify the mode of transmission and incubation period. ries 14 61 contributed data on 17690 isolates whichThese drugs are more costly toxic and less effective thanfirst-line drugs used for routine treatment of TB with other diseases resistance to TB drugs Strength of the recommendationAPreferred should generally be offeredBAlternative acceptable to offerCOffer when preferred or alternative regimens cannot be givenDShould generally not be offeredEShould OCTOBER 2011. Drug Therapy Monitoring.  . Definition. Drug therapy monitoring, also known as Therapeutic Drug Monitoring (TDM), is a means of monitoring drug levels in the blood.. Purpose. TDM is employed to measure blood drug levels so that the most effective dosage can be determined, with toxicity prevented. TDM is also utilized to identify noncompliant patients (those patients who, for whatever reason, either cannot or will not comply with drug dosages as prescribed by the physician).. — 91 — and extensively drug resistant TB — 92 — and extensively drug resistant TBficient anti TB programs were the most affected by multi-resistance. Global resistance figures prov Courses in Therapeutics and Disease State Management. Learning Objectives (Slide 1 of 2). Identify the risk factors for TB infection and active disease.. Design an appropriate therapeutic plan for latent tuberculosis in immunocompetent, immunocompromised, and special patient populations.. The treatment of drug-susceptible. and drug-resistant tuberculosis. Antwerp, 11 April 2019. Hans L Rieder. Efficacy, effectiveness, efficiency…. Efficacy. What can the drug do? (ideal conditions, simulated in clinical trial settings: factually evaluating . & . Update on HCV . blood bank protocol. . Overview - . diagnostic tests. Serologic . assays: . specific antibody to hepatitis C virus (anti-HCV). Molecular . assays: HCV nucleic acid . (. nucleic.